[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"interstitial-lung-diseases\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:interstitial-lung-diseases":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,40,63,83,113,148,172,195,216,239],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100634538","phase-3-fibroneer-act-a-study-to-test-whether-nerandomilast-helps-people-with-fibrosing-interstitial-lung-disease-at-risk-for-disease-progression-100634538",false,"NCT07540988","FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progression","A Double-blind, Randomized, Placebo-controlled Trial Investigating the Efficacy and Safety of Nerandomilast Over at Least 52 Weeks in Patients With Fibrosing Interstitial Lung Disease at Risk for Disease Progression (FIBRONEER-ACT)","Inclusion criteria :\n\n1. Male and female individuals ≥18 years of age at the time of first signed informed consent at Visit 1a\n2. Signed and dated written informed consent in accordance with International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) - Good Clinical Practice (GCP) and local legislation prior to admission to the trial\n3. Diagnosis of fibrosing interstitial lung disease (ILD) other than idiopathic pulmonary fibrosis (IPF) as established by the investigator\n4. Presence of fibrotic lung disease on high resolution computed tomography (HRCT), defined as reticulation with traction bronchiectasis\u002F bronchiolectasis and\u002For honeycombing, and extent of fibrosis ≥10%, as assessed by central review prior to randomization\n5. Time since ILD diagnosis ≤3 years before randomization\n6. FVC ≥45% of predicted normal at Visit 1\n7. Diffusing capacity of the lungs for carbon monoxide (DLCO) ≥25% of predicted normal corrected for hemoglobin (Hb) at Visit 1\n8. Patients treated with permitted immunosuppressive\u002Fimmunomodulatory agents for an underlying systemic disease (e.g. methotrexate (MTX), azathioprine (AZA)) need to be on stable treatment for at least 12 weeks prior to Visit 1 and during screening period\n9. Further inclusion criteria apply.\n\nExclusion criteria :\n\n1. Known diagnosis of idiopathic pulmonary fibrosis (IPF) based on multidisciplinary discussion (MDD) and according to the American Thoracic Society (ATS)\u002FEuropean Respiratory Society (ERS) 2022 guidelines\n2. Known diagnosis of autoimmune-ILDs other than rheumatoid arthritis-associated ILD (RA-ILD)\n3. Known diagnosis of sarcoidosis\n4. Patients with predominant features of organizing pneumonia on HRCT, as assessed by central review\n5. Patients who developed ILD due to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection\u002FCoronavirus Disease 2019 (COVID-19) (based on investigators judgement)\n6. Meeting criteria for progressive pulmonary fibrosis (PPF), as assessed by investigator\n7. Meeting criteria for treatment with currently approved therapies for the fibrosing ILD (e.g. PPF), as assessed by investigator\n8. Prior or current use of nerandomilast, nintedanib, or pirfenidone\n9. Further exclusion criteria apply.","ALL","18 Years",{"count":19,"type":20},466,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","This study is open to adults with fibrosing interstitial lung disease (ILD) other than idiopathic pulmonary fibrosis (IPF). People can join the study if they have been diagnosed with this condition within the last 3 years and are at risk of developing progressive pulmonary fibrosis (PPF). The purpose of this study is to find out whether a medicine called nerandomilast helps people with fibrosing interstitial lung disease who may be at risk for their disease getting worse.\n\nParticipants are put into 2 groups randomly, which means by chance. One group takes nerandomilast tablets, and the other group takes placebo tablets. Placebo tablets look like nerandomilast tablets but do not contain any medicine. Nerandomilast is a type of medicine that may help reduce lung function decline and slow disease progression.\n\nParticipants are in the study for up to about 2 years and 4 months. During this time, they visit the study site regularly. Doctors regularly test lung function using methods like spirometry to measure forced vital capacity (FVC, maximum amount of air a participant can blow out after taking a deep breath) and DLCO (diffusing capacity of the lungs for carbon monoxide; it estimates how well oxygen moves from the lungs into the blood). Additionally, high-resolution computed tomography (HRCT) is performed to monitor how the lung condition is changing over time. The results are compared between the groups to see whether the treatment works. The doctors also regularly check participants' health and take note of any unwanted effects.",[26],"Interstitial Lung Diseases","NOT_YET_RECRUITING","2026-06-23",{"date":30,"type":31},"2026-06-24","ACTUAL",{"date":33,"type":20},"2026-08-28",{"date":35,"type":20},"2028-12-12",{"name":37,"class":38},"Boehringer Ingelheim","INDUSTRY",142,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":47,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":21,"phases":50,"briefSummary":51,"conditions":52,"keywords":4,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":56,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":62},"100608466","phase-3-a-study-to-test-whether-nerandomilast-can-help-slow-down-changes-in-the-lung-in-people-with-a-family-history-of-pulmonary-fibrosis-100608466","NCT07201922","A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary Fibrosis","A Double Blind, Randomized, Placebo-controlled Exploratory Trial to Investigate the Efficacy and Safety of Nerandomilast Over 24 Months When Administered in Individuals With Interstitial Lung Abnormalities and a Family History of Pulmonary Fibrosis to Reduce the Risk of Worsening (DROP-FPF)","Inclusion Criteria:\n\n* Individuals ≥40 years of age at the time of first signed informed consent at Visit 1a\n* Participants must have at least 1 first-degree relative (biological parent, sibling, or child) with confirmed pulmonary fibrosis (idiopathic pulmonary fibrosis \\[IPF\\], idiopathic nonspecific interstitial pneumonia \\[NSIP\\], and\u002For pulmonary fibrosis due to known genetic cause \\[e.g. short telomere syndrome, mucin 5B (MUC5B) mutation, surfactant protein mutations\\])\n* High resolution computed tomography (HRCT) scan with evidence of interstitial lung abnormalities involving at least 5% of a single lung zone or interstitial lung disease (ILD), based on central evaluation\n* Forced vital capacity (FVC) ≥80% of predicted normal at Visit 1b\n* Diffusing capacity of the lungs for carbon monoxide (DLCO) corrected for hemoglobin ≥70% of predicted normal at Visit 1b Further inclusion criteria apply.\n\nExclusion Criteria:\n\n* Prior known pulmonary fibrosis that, in the opinion of the Investigator, requires treatment with approved therapies\n* Prebronchodilator forced expiratory volume in 1 second (FEV1)\u002FFVC \\\u003C0.7 at Visit 1b\n* HRCT findings consistent with probable or definite usual interstitial pneumonia (UIP) pattern\n* Any medical condition that is known to predispose to the development of pulmonary fibrosis (e.g. known connective tissue disease)\n* Prior or current use of nerandomilast, nintedanib, or pirfenidone Further exclusion criteria apply.","40 Years",{"count":49,"type":20},80,[23],"This study is open to people aged 40 years or older who have at least 1 family member with pulmonary fibrosis. Pulmonary fibrosis is a condition where lung tissue becomes scarred, making it harder to breathe. People can join if a lung scan shows early changes in the lung, called interstitial lung abnormalities, which may lead to lung scarring. People with family members who have pulmonary fibrosis are more likely to develop it themselves. That is why it is important to check early for lung changes and find ways to prevent the condition from getting worse. The purpose of this study is to find out whether a medicine called nerandomilast can help slow down changes in the lung in people with a family history of pulmonary fibrosis.\n\nParticipants are put into one of 2 groups randomly, which means the group is chosen by chance. One group takes nerandomilast tablets, and the other group takes placebo tablets. Placebo tablets look like nerandomilast tablets but do not contain any medicine. Participants take a tablet twice a day for about 2 to 3 years. There is a 3 out of 5 chance that participants will receive nerandomilast instead of the placebo.\n\nParticipants are in the study for about 2 to 3 years. Participants visit the study site multiple times: more frequently during the first 2 years (about every 3 months), and then every 6 months thereafter. In the 3rd year, participants also have phone calls with the site staff every 3 months.\n\nDoctors regularly test lung function and take chest scans to see if the treatment works. The results are compared between the 2 groups to see if nerandomilast helps. The doctors also check participants' health and take note of any unwanted effects.",[53,54,26],"Familial Pulmonary Fibrosis","Interstitial Lung Abnormalities","RECRUITING",{"date":30,"type":31},{"date":58,"type":31},"2026-02-10",{"date":60,"type":20},"2029-05-23",{"name":37,"class":38},56,{"id":64,"slug":65,"hasResults":11,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":4,"eligibilityCriteria":69,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":70,"targetDuration":4,"studyType":21,"phases":72,"briefSummary":73,"conditions":74,"keywords":4,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":76,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},"100578076","phase-3-a-study-to-test-whether-nerandomilast-helps-people-with-lungfibrosis-related-to-rheumatic-diseases-100578076","NCT06806592","A Study to Test Whether Nerandomilast Helps People With Lungfibrosis Related to Rheumatic Diseases","A Double Blind, Randomised, Placebo-controlled Trial Evaluating the Efficacy and Safety of Nerandomilast Over at Least 26 Weeks in Patients With Systemic Autoimmune Rheumatic Diseases Associated Interstitial Lung Diseases (SARD-ILD)","Inclusion Criteria:\n\n* Participant has systemic autoimmune rheumatic diseases associated interstitial lung diseases (SARD-ILD), defined as\n\n  * Diagnosis by a rheumatologist (or equally qualified medical physician) with at least 1 of the following SARDs: Rheumatoid arthritis (RA), systemic sclerosis (SSc) (participants must be anticentromere auto-antibody negative), idiopathic inflammatory myopathy (IIM), Sjögren's disease, or mixed connective tissue disease (MCTD) (participants must be anti-U1-ribonucleoprotein particle (RNP) auto-antibody positive)\n  * Presence of fibrotic interstitial lung disease (ILD) on high-resolution computed tomography (HRCT), defined as presence of reticular abnormality with traction bronchiectasis with or without honeycombing (HC), with disease extent \\>10% on HRCT performed within 12 months of Visit 1 or, if historical scan is not available, on baseline HRCT taken prior to Visit 2, as confirmed by central review\n* No lung function improvement and no clinically significant ILD improvement as a treatment response to immunosuppressant (IS) therapy according to both criteria:\n\n  * No improvement in absolute forced vital capacity (FVC) % predicted \\>5% within the 15 months prior to Visit 1, as measured by 2 spirometry assessments that must be ≥3 months apart. (Note: 1: In the case of multiple PFTs over the 15 months prior to screening, exceptional values of absolute change in FVC % predicted \\>5% are acceptable if the overall trend of FVC % predicted is declining or stable; note 2: Visit 1 spirometry may be used to fulfill the inclusion criterion if there is only 1 spirometry reading in the 15 months prior to Visit 1)\n  * No clinically significant improvement in ILD based on clinician's judgement (including symptoms, imaging\u002FHRCT, or other assessments as considered relevant and documented by the Investigator)\n* FVC ≥45% of predicted normal at Visit 1\n* Diffusing capacity of the lungs for carbon monoxide (DLCO) ≥25% of predicted normal corrected for haemoglobin (Hb) within 3 months prior to or at Visit 1\n* Participants must be on stable treatment with any IS agent for ≥6 months (or ≥3 months for participants with IIM-ILD) prior to visit 2, with the following specifications:\n\n  * If using prednisone, participants must be on stable dose for ≥4 weeks prior to Visit 2\n  * If using rituximab, participants must have completed their first cycle \\>6 months prior to Visit 2\n* If using nintedanib, participants must be on a stable dose for ≥12 weeks prior to Visit 2\n* In the opinion of the Investigator, no change in background standard of care (SoC) treatment with immunosuppressant (IS), immunomodulator (IM), or nintedanib is planned\n* Further inclusion criteria apply\n\nExclusion Criteria:\n\n* Organising pneumonia as predominant pattern in the HRCT\n* Prebronchodilator forced expiratory volume in 1 second (FEV1)\u002F forced vital capacity (FVC) \\\u003C0.7 at Visit 1\n* Acute ILD exacerbation within 3 months prior to Visit 1 and\u002For during the screening period, based on Investigator judgement\n* Active vasculitis, unstable or uncontrolled within 8 weeks prior to Visit 1 or during the screening period\n* Any suicidal behaviour in the past 2 years\n* Any suicidal ideation of type 4 or 5 on the Columbia-Suicide Severity Rating Scale (C-SSRS) in the past 3 months or at Visit 1, and\u002For at Visit 2\n* Use of any of the following medications: cyclophosphamide within 6 months of Visit 1, pirfenidone within 8 weeks of Visit 1\n* Further exclusion criteria apply",{"count":71,"type":20},400,[23],"Adults 18 years of age and older or above legal age with lung fibrosis related to systemic autoimmune rheumatic disease can participate in this study. People can only take part if they show no improvement in lung function after standard treatment with immunosuppressant medicine. The main purpose of this study is to find out how a medicine called nerandomilast affects the lungs in people with systemic autoimmune rheumatic disease.\n\nParticipants are put into 2 groups randomly, which means by chance. One group takes nerandomilast tablets and the other group takes placebo tablets. Placebo tablets look like nerandomilast tablets but do not contain any medicine. Participants take a tablet 2 times a day for at least 26 weeks and up to 1 year. Participants continue immunosuppressant treatment for their underlying rheumatic disease.\n\nParticipants are in the study for about 7.5 to 13 months depending on when they join the study. During this time, they visit the study site about 9 to 10 times. At study visits, participants have lung function tests. At select visits, chest imaging is performed. Participants fill in questionnaires about their symptoms and quality of life. The results between the 2 groups are compared to see whether the treatment works. The doctors also regularly check participants' health and take note of any unwanted effects.",[26,75],"Systemic Autoimmune Rheumatic Diseases Associated Interstitial Lung Diseases",{"date":30,"type":31},{"date":78,"type":31},"2025-09-13",{"date":80,"type":20},"2027-07-30",{"name":37,"class":38},158,{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":87,"acronym":4,"eligibilityCriteria":88,"healthyVolunteers":89,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":90,"targetDuration":4,"studyType":92,"phases":4,"briefSummary":93,"conditions":94,"keywords":98,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":112},"100092968","a-study-of-the-natural-progression-of-interstitial-lung-disease-ild-100092968","NCT00470327","A Study of the Natural Progression of Interstitial Lung Disease (ILD)","Inclusion Criteria:\n\n* Interstitial lung disease\n\nExclusion Criteria:\n\n* Does not have Interstitial lung disease",true,{"count":91,"type":20},4000,"OBSERVATIONAL","We propose to acquire data and blood samples on all patients being cared for by the Interstitial Lung Disease (ILD) program. Additionally, we will collect data and blood samples from a control group for comparator purposes. In doing so, we will be able to describe the \"phenotypic\" expression of these diseases.",[26,95,96,97],"Idiopathic Pulmonary Fibrosis","Sarcoidosis","Connective Tissue Disorder",[99,100,96,101],"Interstitial lung diseases","idiopathic pulmonary fibrosis","mRNA and cytokine expression","2026-06-05",{"date":104,"type":31},"2026-06-09",{"date":106,"type":31},"2005-09",{"date":108,"type":20},"2030-12",{"name":110,"class":111},"University of Chicago","OTHER",1,{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":119,"eligibilityCriteria":120,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":121,"targetDuration":4,"studyType":21,"phases":123,"briefSummary":125,"conditions":126,"keywords":134,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":112},"100521365","ultrasound-and-respiratory-physiological-signals-in-lung-diseases-100521365","NCT06068647","Ultrasound and Respiratory Physiological Signals in Lung Diseases","Synergistic Assessment of Ultrasound Data and Respiratory physiOlogical Signals in luNg Diseases","SAURON","Inclusion Criteria:\n\n* inpatients admitted to the hospital due to diffuse interstitial lung diseases during exacerbation OR infectious interstitial pneumonia not caused by SARS-CoV-2 OR acute exacerbation of chronic obstructive pulmonary disease.\n* Outpatients with pulmonary paraseptal and\u002For panlobular emphysema and\u002For chronic obstructive pulmonary disease during stable phase.\n* Patients able to give written informed consent.\n\nExclusion Criteria:\n\n* history of skin irritation, redness, itching or allergic cutaneous symptoms.\n* Allergic reactions to adhesives or hydrogels.\n* Family history of adhesive skin allergies.\n* Presence of severe skin conditions such as wounds, burns or on any damaged skin.\n* Presence of strong magnetic fields in the study setting.\n* Presence of electromagnetic disturbances or significant ionizing radiation sources which might lead to signal artifacts.\n* Use of external cardiac defibrillators.\n* Use of diaphragmatic pacers.\n* Use of extra cardiac stimulators.\n* Pregnancy.\n* Pediatric population.",{"count":122,"type":20},25,[124],"NA","The use of lung ultrasound is instrumental in the evaluation of many chest pathologies and its ability to detect pleuro-pulmonary pathology is widely accepted.\n\nHowever, the use of ultrasound to explore the state of the peripheral lung parenchyma, when the organ is still aerated, is a relatively new application.\n\nHorizontal and vertical artifacts are separate and distinct artifacts that can be seen during ultrasound examination of the lungs. While the practical role of lung ultrasound artifacts is accepted to detect and monitor many conditions, further research is needed for the physical interpretation of ultrasound artifacts. These artifacts are diagnostic signs, but we don't fully understand their origin.\n\nThe artifactual information deriving from the surface acoustic interaction, beyond the pleural line, in the ultrasound images of the normally aerated and non-deflated lung, represents the final result of complex interactions of acoustic waves with a specific three-dimensional structure of the biological tissue. Thus, the umbrella term \"vertical artifacts\" oversimplifies many physical phenomena associated with a pathological pleural plane. There is growing evidence that vertical artifacts are caused by physiological and pathological changes in the superficial lung parenchyma.\n\nTherefore, the need emerges to explore the physical phenomena underlying the artifactual ultrasound information deriving from the surface acoustic interaction of ultrasound with the pleuro-pulmonary structures.",[127,26,128,129,130,131,132,133],"Interstitial Lung Disease","Interstitial Pneumonia","Chronic Obstructive Pulmonary Disease","Emphysema or COPD","Ultrasonography","Ultrasound Imaging","Ultrasound",[133,132,131,135,136,137,138],"Emphysema","Chronic obstructive pulmonary disease","Interstitial pneumonia","Interstitial lung disease","2026-05-19",{"date":141,"type":31},"2026-05-20",{"date":143,"type":31},"2023-03-22",{"date":145,"type":20},"2026-09-30",{"name":147,"class":111},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":149,"slug":150,"hasResults":11,"nctId":151,"briefTitle":152,"officialTitle":152,"acronym":153,"eligibilityCriteria":154,"healthyVolunteers":89,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":155,"targetDuration":4,"studyType":92,"phases":4,"briefSummary":157,"conditions":158,"keywords":159,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":163,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":112},"100518913","interstitial-lung-disease-a-study-from-infancy-to-elderly-including-relatives-100518913","NCT06036719","Interstitial Lung Disease: A Study From Infancy to Elderly Including Relatives","RaDiCo-ILD 2","Inclusion Criteria:\n\nConfirmed diagnosis of IIP established based on clinical, radiological, or functional criteria.\n\nConfirmed diagnosis of non-IPF progressive fibrotic interstitial lung disease (PF-ILD) with fibrosis ≥ 10% on CT scan, disease worsening not related to pulmonary embolism, decompensated heart failure, or lower respiratory tract infection, and disease progression despite \"appropriate management\" evaluated over a period of up to 24 months:\n\n* A relative decline in Forced Vital Capacity (FVC) of at least 10% from predicted value, with or without clinical deterioration, or\n* A combination of at least 2 of the following criteria: a relative decline in FVC between 5% and 10% from predicted value, worsening respiratory symptoms, increased extent of pulmonary fibrosis on thoracic CT scan.\n\nConfirmed diagnosis of Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) (American College of Rheumatology criteria), with a total score ≥ 9 and disease extent involving ≥ 10% of the lungs (defined by reticular abnormalities, honeycombing, and ground-glass opacities) on high-resolution CT (HRCT) scan.\n\nFor relatives: First degree relatives of patients carrying a mutation in TERT, TERC, RTEL1, TINF2, DKC1, PARN genes, and other telomere related genes that may be described in the future and included.",{"count":156,"type":20},3000,"The concerned patients are children and adults suffering from idiopathic interstitial pneumonias, other chronic fibrosing interstitial pneumonias with a progressive phenotype, and interstitial pneumonia associated with Scleroderma and related cases of patients carrying a mutation on one of the telomere-associated genes.\n\nThis is a national, observational, longitudinal, multicenter study that will be conducted retrospectively and prospectively. It aims to collect consistent and comparable clinical data for patients and their relatives, whether they carry a mutation or not, affected by diffuse idiopathic interstitial pneumopathy.\n\nThe expected duration of the study, including data analysis, is approximately 10 years (5 years for participant enrollment and 5 years of follow-up, in addition to the steps for data management and statistical analyses).\n\nEach participating center will inform every participant by providing an information sheet, and their written consent will be obtained before including them in the study and commencing data collection.\n\nProspective medical data will be collected at 6 months to 1 year after enrollment and then at least once per year for patients up to 5 years and 5 years for their relatives.\n\nParticipants will complete a self-questionnaire during their regular follow-up consultations or by accessing a secure interface.",[26],[160,95,161,162],"Pediatric Interstitial Lung Diseases","Pediatrics \u002F adult","Idiopathic Interstitial Pneumonia",{"date":164,"type":31},"2026-02-12",{"date":166,"type":31},"2022-01-19",{"date":168,"type":20},"2031-03-19",{"name":170,"class":171},"Institut National de la Santé Et de la Recherche Médicale, France","OTHER_GOV",{"id":173,"slug":174,"hasResults":11,"nctId":175,"briefTitle":176,"officialTitle":176,"acronym":177,"eligibilityCriteria":178,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":179,"targetDuration":4,"studyType":92,"phases":4,"briefSummary":181,"conditions":182,"keywords":183,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":187,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":193,"locationsCount":112},"100557424","advanced-mutidimensional-and-ultra-high-resolution-computed-tomography-to-inspect-cardiopulmonary-involvement-in-progressive-fibrosing-interstitial-lung-diseases-100557424","NCT06537934","Advanced Mutidimensional and Ultra High Resolution Computed Tomography to Inspect Cardiopulmonary Involvement in Progressive Fibrosing Interstitial Lung Diseases","AMICI-ILD","Inclusion Criteria:\n\n• Adult subjects (\\>18 y.o.) with previously known ILD or high likelihood for having ILD including CTD diagnosis since at least 5 years before the project starts in order to increase the prevalence of ILD \\[2\\] who signed an Informed Consent authorizing data collection.\n\nExclusion Criteria:\n\n* Subjects with active infectious disease;\n* known CAD;\n* history of previous percutaneous or surgical revascularization;\n* known cardiomyopathy;\n* previous heart failure;\n* presence of cardiac devices (prosthetic valve, ICD, PM, ICD-CRT, LVAD)\n* previous or active neoplasia;\n* pregnancy and breastfeeding;\n* allergy to iodine contrast agent;\n* claustrophobia;\n* glomerular filtration rate \\\u003C 30mL\u002Fmin\n* impossibility to lay down or breath old\n* absence of informed consent signed",{"count":180,"type":20},123,"Interstitial lung diseases (ILDs) are common chronic disease characterized by high mortality and morbidity, also linked to cardiovascular implication. Cardiovascular complications, occur early in idiopathic pulmonary fibrosis (IPF) and other ILDs without anysymptoms. Symptoms are often misinterpreted and diagnosis delayed to irreversible stages of cardiac dysfunction. Mechanism of cardiac damage, the main cause of mortality, are heterogeneous raging from ischemic heart disease, acceleration of atherosclerosis, to right ventricle dysfunction secondary, to pulmonary hypertension. So an early recognition and accurate staging are fundamental to avoid disease progression and improve outcomes. The identification of a single non-invasive imaging modality able to simultaneously characterize in an accurate and quantitative way the entity of lung and cardiac damage in patients affected by ILD would be useful to improve risk stratification and to guide treatment.",[26],[184,185],"Cardiac fibrosis","Lung interstitial fibrosis","2026-01-14",{"date":188,"type":31},"2026-01-15",{"date":190,"type":31},"2024-09-01",{"date":192,"type":20},"2026-09-01",{"name":194,"class":111},"IRCCS San Raffaele",{"id":196,"slug":197,"hasResults":11,"nctId":198,"briefTitle":199,"officialTitle":200,"acronym":4,"eligibilityCriteria":201,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":202,"targetDuration":204,"studyType":92,"phases":4,"briefSummary":205,"conditions":206,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":207,"lastUpdatePostDateStruct":208,"startDateStruct":210,"completionDateStruct":212,"leadSponsor":214,"locationsCount":4},"100608949","bronchoalveolar-lavage-in-interstitial-lung-diseases-to-characterization-of-specific-inflammatory-cellular-infiltrate-in-different-interstitial-lung-diseases-100608949","NCT07208201","Bronchoalveolar Lavage in Interstitial Lung Diseases to Characterization of Specific Inflammatory Cellular Infiltrate in Different Interstitial Lung Diseases","Clinical Utility of Bronchoalveolar Lavage in Interstitial Lung Diseases","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Clinical suspicion of ILD based on symptoms, clinical examination, and radiological findings or newly diagnosed cases .\n* HRCT findings consistent with ILD\n* Willingness to undergo bronchoscopy with BAL and provide informed consent\n\nExclusion Criteria:\n\n* Hemodynamic instability or ICU admission at time of evaluation\n* Oxygen saturation \\\u003C 88% on room air or \\\u003C 92% on oxygen therapy\n* Absolute contraindications to bronchoscopy (e.g., uncorrected bleeding diathesis, recent myocardial infarction)\n* Associated chronic chest diseases other than ILD (COPD. bronchial asthma and lung cancer )\n* Known active pulmonary infection or recent antibiotic treatment (\\\u003C 2 weeks)\n* Pregnancy",{"count":203,"type":20},66,"2 Years","Interstitial lung disease (ILD) represents a various group of disorders characterized by inflammation and fibrosis within the lung parenchyma.\\[1\\] ILD refers to a group of diffuse parenchymal lung disorders, including a spectrum of conditions such as idiopathic pulmonary fibrosis (IPF), sarcoidosis, and connective tissue disease-associated ILD (CTD-ILD) characterized by inflammation and fibrosis of the interstitium.\n\nILD results in Impaired lung function and, in severe cases, respiratory failure.\\[1\\] Diagnosing ILD is a complex task due to the heterogeneous nature of these disorders.\n\nDistinguishing between different ILD subtypes and identifying disease progression present ongoing challenges in clinical practice. .\\[2\\] BAL emerges as a key investigative tool , allowing for the collection of bronchoalveolar fluid.\n\nThe cellular and molecular composition of BAL fluid provides valuable insights into the underlying pathology, aiding in the differential diagnosis of ILD subtypes.\n\nThe gold standard in BAL analysis is cytological examination by microscopy.\\[3\\] Flow cytometry is an updated method of BAL analysis which can provide quicker and more objective results and, with the appropriate design of antibody panels, accurately quantify the main leukocyte subsets.\n\nSeveral studies have described the usefulness of flowcytometry for the discrimination of sarcoidosis from other lymphocytic pathologies or even to perform leukocyte subset counting in diverse ILDs.\\[4\\]\\[5\\]\n\nBoth microscopic and flowcytometric examination of BAL in ILD are complementary tools that provide comprehensive information about the cellular landscape of the lower respiratory tract ,conclusive for:\n\nAccurate diagnosis\n\nPrimary aim:\n\nCharacterization of specific inflammatory cellular infiltrate in different interstitial lung diseases.\n\n\\- Secondary aims:\n\n1. Correlation between clinical ,radiological and inflammatory cellular pattern as regards BAL findings of different interstitial lung diseases\n2. Assessment of impact on outcome, prognosis and survival of the disease as regards management modification after BAL characterization",[26],"2025-09-27",{"date":209,"type":31},"2025-10-06",{"date":211,"type":20},"2025-12-04",{"date":213,"type":20},"2027-12-04",{"name":215,"class":111},"Maha Ahmed Abd EL Gawad Mohammed Okasha",{"id":217,"slug":218,"hasResults":11,"nctId":219,"briefTitle":220,"officialTitle":221,"acronym":4,"eligibilityCriteria":222,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":223,"targetDuration":4,"studyType":92,"phases":4,"briefSummary":225,"conditions":226,"keywords":227,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":230,"lastUpdatePostDateStruct":231,"startDateStruct":233,"completionDateStruct":235,"leadSponsor":237,"locationsCount":4},"100601957","interstitial-lung-diseases-in-respiratory-icu-100601957","NCT07117253","Interstitial Lung Diseases in Respiratory ICU","Factors Affecting Outcome of Patients With Interstitial Lung Diseases in Respiratory Intensive Care Unit","Inclusion Criteria:\n\n* Patients who had diagnosis of interstitial lung diseases required admission in respiratory ICU\n\nExclusion Criteria:\n\n* Patients with respiratory diseases other than ILD",{"count":224,"type":20},50,"This is Prospective observational study to analyze the clinical features, risk factors, outcome,mortality rates in interstitial lung diseases patients who required admission in Respiratory ICU",[26],[228,229],"interstitial lung diseases","outcome in icu","2025-08-11",{"date":232,"type":31},"2025-08-12",{"date":234,"type":20},"2025-08-01",{"date":236,"type":20},"2026-08-29",{"name":238,"class":111},"Sohag University",{"id":240,"slug":241,"hasResults":11,"nctId":242,"briefTitle":243,"officialTitle":244,"acronym":245,"eligibilityCriteria":246,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":247,"targetDuration":204,"studyType":92,"phases":4,"briefSummary":249,"conditions":250,"keywords":251,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":255,"lastUpdatePostDateStruct":256,"startDateStruct":258,"completionDateStruct":260,"leadSponsor":262,"locationsCount":112},"100540514","lets-get-functional-functional-status-in-people-with-interstitial-lung-disease-100540514","NCT06317831","LetS Get fUnctional! FuNctional Status in pEople With intersTitial Lung Disease","LetS Get fUnctional! FuNctional Status in pEople With intersTitial Lung Disease - the SUNSET Study","SUNSET","Inclusion Criteria:\n\n* ≥18 years\n* Diagnosed with any type of ILD\n* Fluent in Portuguese\n* Able to provide informed consent.\n\nExclusion Criteria:\n\n* Other respiratory diseases\n* A history of acute cardiac\u002Frespiratory condition in the previous month\n* Present signs of cognitive impairment\n* Significant cardiovascular, neurological and\u002For musculoskeletal disease that may limit their participation\n* Current neoplasia\n* Other autoimmune diseases (aside from ID).",{"count":248,"type":20},150,"This study aims to i) To characterize the functional status and explore the determinants of functional status decline of people with IlD ii)To determine the measurement properties of functional status instruments in people with Interstitial lung diseases (ILD) iii) To identify the impact of ILD and the participants' perspectives on functional status through interviews iv) Explore the progression of functional status progression in people with ILD and v) Develop a multidimensional index, incorporating functional status parameters, to predict mortality in people with ILD.\n\nPatients with ILD will be recruited via the pulmonology services at hospitals, namely from Centro Hospitalar de Vila Nova de Gaia\u002FEspinho (CHVNG\u002FE), Centro Hospitalar do Baixo Vouga (CHBV) and Centro Hospitalar de Entre o Douro e Vouga (CHEDV). Sociodemographic, clinical characteristics (i.e., smoking habits, vital signs and symptoms), anthropometric (i.e., height and weight to compute body mass index) and general clinical data (i.e., medication, oxygen therapy, non-invasive ventilation, acute exacerbations, hospitalizations and number of hospital admissions in the last month and year, length of stay), as well as prior and follow-up spirometric measurements and arterial blood gas will be collected from clinical records for patients' characterization. Mortality and rehospitalizations will be explored during the study period. Peripheral muscle strength, functional status, daily physical activity, self-reported symptoms, functional status, impact of the disease and health-related quality of life. Qualitative data from interviews.\n\nThe assessments will be conducted at 6 time points: baseline and 1 week after for instrument validation, followed by assessments every 6 months for 2 years.\n\nIt is expected that: i) Functional status limitations can be comprehensively identified and measured in individuals with ILD. ii) Some measures are valid and reliable indicators of functional status in individuals with ILD. iii) Different profiles of functional status progression will be identified in individuals with ILD, including stable, slow, and fast decline. iv) A multidimensional index incorporating functional status will improve the accuracy of predicting mortality and outperform the predictive ability of the current GAP Index.",[26],[252,99,253,254],"Functional Status","Assessment","Patient-centered care","2024-04-29",{"date":257,"type":31},"2024-04-30",{"date":259,"type":31},"2024-04-01",{"date":261,"type":20},"2028-07-30",{"name":263,"class":111},"Aveiro University"]